ALPHA Sitagliptin Add on to Metformin (0431-103)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 4

Conditions: Diabetes Mellitus

Treatments: Drug: sitagliptin phosphate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00833027

MK0431-103

0431-103

2009_527

Details and patient eligibility

About

Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin

Enrollment: 608 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patient Is Currently On Monotherapy With Metformin For At Least 10 Weeks Prior To Study Entry

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

608 participants in 1 patient group

1

Experimental group

Description:

Sitagliptin

Treatment:

Drug: sitagliptin phosphate